Moderna (MRNA) just secured European marketing authorization for mCOMBRIAX, the world’s first combined flu and COVID vaccine for adults 50 and over. This development is putting fresh attention on how this new product might influence the stock.
See our latest analysis for Moderna.
Despite a 4.95% 1 day share price decline to US$52.85 and a softer 7 day share price return of 3.35%, Moderna’s 30 day and 90 day share price returns of 2.94% and 8.50% indicate recent momentum alongside a 71.26% year to date share price return and a 92.95% 1…
